Atea Pharmaceuticals, Inc. ((AVIR)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Atea Pharmaceuticals, Inc. is conducting a Phase 1 study titled A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Bemnifosbuvir and Ruzasvir Administered as a Fixed-Dose Combination in Adult Participants With Severe Renal or Hepatic Impairment in Comparison to Healthy Participants. The study aims to assess the impact of severe hepatic or renal impairment on the pharmacokinetics of a single dose of Bemnifosbuvir/Ruzasvir, which is significant for understanding drug safety and efficacy in these populations.
Intervention/Treatment: The intervention being tested is a fixed-dose combination of the drugs Bemnifosbuvir and Ruzasvir. This combination is intended to evaluate its safety and pharmacokinetics when administered as a single dose to different groups, including those with severe renal or hepatic impairment.
Study Design: This interventional study is non-randomized with a parallel assignment. There is no masking involved, meaning all participants and researchers know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to gather data on the drug’s behavior in the body under different health conditions.
Study Timeline: The study began on March 24, 2025, with the latest update submitted on September 29, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The ongoing study by Atea Pharmaceuticals could influence its stock performance by providing insights into the safety and effectiveness of its drug combination in patients with severe organ impairments. Positive results may enhance investor confidence and position Atea competitively within the pharmaceutical industry, particularly against companies focusing on similar therapeutic areas.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.